Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men

Cancer Research

Volumn 62, Issue 13, 2002, Pages 3609-3614

  Adam, Bao Ling ^a,b   Qu, Yinsheng ^d   Davis, John W ^a,b   Ward, Michael D ^a,b   Clements, Mary Ann ^a,b   Cazares, Lisa H ^a,b   Semmes, O John ^a,b   Schellhammer, Paul F ^a,b   Yasui, Yutaka ^d   Feng, Ziding ^d   Wright, George L ^a,b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Sentara Cancer Resource Centers   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALGORITHM; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ANTIGEN STRUCTURE; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DECISION THEORY; DISEASE MARKER; DNA FINGERPRINTING; EARLY DIAGNOSIS; HUMAN; IONIZATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEOMICS; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; ALGORITHMS; ARTIFICIAL INTELLIGENCE; BLOOD PROTEINS; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PATTERN RECOGNITION, AUTOMATED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 0036645099     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends
2. PSA, PSA density. PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL
3. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer
4. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: Prostate specific antigen cure rates appear constant between 2 and 9 ng/ml
5. Proteomics in early detection of cancer
6. Proteomic approaches to biomarker discovery in prostate and bladder cancers
7. Differential screening and mass mapping of proteins from premalignant and cancer cell lines using nonporous reversed-phase HPLC coupled with mass spectrometric analysis
8. Protein profiles in sera of patients with malignant cutaneous melanoma
9. Tandem mass spectrometry methods for definitive protein identification in proteomics research
10. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry
11. Bactericidal domain of lactoferrin: Detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry
12. Proteinchip surface enhanced laser desorption/ionization (SELDI) mass spectrometry: A novel proteomic technology for detection of prostate cancer biomarkers in complex protein mixtures
13. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine
14. Receiver operating characteristic methodology
15. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests
16. Use of proteomic patterns in serum to identify ovarian cancer
17. Preoperative serum prostate specific antigen (PSA) below 10 μg/L predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure
18. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease